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Epithelial mast cells are generally present in the airways of patients with allergic asthma
that are inadequately controlled. Airway mast cells (MCs) are critically involved in allergic
airway inflammation and contribute directly to the main symptoms of allergic patients.
Phosphodiesterase 3 (PDE3) tailors signaling of cyclic adenosine monophosphate (cAMP)
and cyclic guanosine monophosphate (cGMP), which are critical intracellular second
messenger molecules in various signaling pathways. This paper investigates the
pathophysiological role and disease-modifying effects of PDE3 in mouse bone marrow-
derived MCs (bmMCs), human LAD2- and HMC1 mast cell lines, human blood basophils,
and peripheral blood-derived primary human MCs (HuMCs). In a chronic house dust mite
(HDM)-driven allergic airway inflammation mouse model, we observed that PDE3
deficiency or PDE3 inhibition (PDE3i) therapy reduced the numbers of epithelial MCs,
when compared to control mice. Mouse bone marrow-derived MCs (bmMCs) and the
human HMC1 and LAD2 cell lines predominantly expressed PDE3B and PDE4A. BmMCs
from Pde3−/− mice showed reduced loss of the degranulation marker CD107b compared
with wild-type BmMCs, when stimulated in an immunoglobulin E (IgE)-dependent manner.
Following both IgE-mediated and substance P-mediated activation, PDE3i-pretreated
basophils, LAD2 cells, and HuMCs, showed less degranulation than diluent controls, as
measured by surface CD63 expression. MCs lacking PDE3 or treated with the PDE3i
enoximone exhibited a lower calcium flux upon stimulation with ionomycine. In conclusion
PDE3 plays a critical role in basophil and mast cell degranulation and therefore its inhibition
may be a treatment option in allergic disease.
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Mast cells (MCs) play a key role in human allergic airway
inflammation. The observation of bronchial epithelial MCs in
asthmatic patients (Braunstahl et al., 2003) is an indication that
the presence and location of MCs are important. Mast cell and
basophil dynamics were also observed in the nasal mucosa of
allergic rhinitis patients (KleinJan et al., 2000). The findings of
elevated numbers of MCs and increased serum tryptase levels,
suggesting MC activation, implicate MCs in various lung
diseases, including idiopathic pulmonary fibrosis and
sarcoidosis (Bargagli et al., 2009; Wygrecka et al., 2013). It has
been reported that the presence of pulmonary neuroendocrine
cells amplify allergic asthma responses by the release of the
neuropeptides calcitonin gene-related peptide (CGRP) and
substance P (SP), both of which can act as MC stimulators
(Sui et al., 2018).
Localization of MCs is an important pathophysiological
feature; in healthy controls they are absent in the epithelium
but present in submucosal airways. The presence of MCs in
the epithelium or in close proximity to smooth muscle airway
cells (Brightling et al., 2002; Bradding et al., 2006; Bradding
and Brightling, 2007) contributes to smooth muscle
hyperplasia via TGFb and b-tryptase (Woodman et al.,
2008). In uncontrolled allergic asthma patients the total
number of MCs and MCTC (MC containing tryptase and
chymase) in the alveolar parenchyma was found to correlate
negatively with FEV1% predicted (Andersson et al., 2011;
Andersson et al., 2018). In these patients the numbers of
mast cells expressing FceR1 and TGFb are increased. These
findings indicate the connection between disease and
parenchymal MCs in uncontrolled asthmatics. In addition,
the amount of collagen deposition correlates with the number
of MCs in the parenchyma (Andersson et al., 2011). In vivo
mast cell studies are hampered by the fact that staining for
serine proteases is not always easy to interpret because MCs
degranulate during allergen challenge; the number of serine
protease-positive cells drops, because degranulated cells are
not positive anymore (Balzar et al., 2011). Basophil and MC
accumulation occurs in the airways after allergen inhalation
and/or challenges of allergic patients (Gauvreau et al., 2000;
KleinJan et al., 2000; Braunstahl et al., 2003), and in fatal
asthma (Perskvist and Edston, 2007; Woodman et al., 2008; Yu
et al., 2011). In allergy, mast cell and basophil degranulation is
initiated during the early-phase reaction and continues to the
late-phase reaction (Togias et al., 1988; Fokkens et al., 1992; de
Graaf-in't Veld et al., 1997; KleinJan et al., 2000).
MC activation by immunoglobulin E (IgE)-dependent (i.e.,
“allergic”) or other mechanisms release a diverse spectrum of
mediators that induce local effects on blood vessels, nerves,Abbreviations: AAI, allergic airway inflammation; AHR, airway hyper-
responsiveness; BAL, broncho-alveolar lavage; cAMP, cyclic adenosine
monophosphate; cGMP, cyclic guanosine monophosphate; DC, dendritic cell;
HDM, house dust mite; HRP, horseradish peroxidase; MLN, mediastinal lymph
node; MC, mast cell; PBS, phosphate buffered saline; PDE, phosphodiesterase;
PDE3i, phosphodiesterase 3 inhibitor(s)/inhibition; SP, substance P.
Frontiers in Pharmacology | www.frontiersin.org 2mucous glands, epithelial cells, airway smooth-muscle cells,
and immune cells (Bradding et al., 2006). Analyses in chronic
asthma mouse models indicated that MCs can contribute to the
establishment of chronic eosinophilic airway inflammation (Yu
et al., 2011). They also contribute to features of tissue remodeling
that resemble those observed in asthma patients, including
increased numbers of mucus-secreting goblet cells in the
airway epithelium and increased deposition of interstitial
collagen (Yu et al., 2011; Li et al., 2019).
In the context of allergic airway inflammation and asthma,
phosphodiesterase 3 (PDE3) and PDE4 are widely expressed
in airway cells, including epithelial and endothelial cells,
smooth muscle cells, and inflammatory cells (Beavo, 1995;
Blease et al., 1998; Wright et al., 1998; Myou et al., 1999;
Souness et al., 2000; Boswell-Smith et al., 2006). Whereas both
PDE3 and PDE4 are cyclic adenosine monophosphate
(cAMP)-degrading enzymes, only PDE3 degrades cyclic
guanosine monophosphate (cGMP) as well. PDE4 is an
asthma-susceptibility gene (Himes et al., 2009). PDE
inhibition (PDEi) appears to act effectively on immune cells,
as well as on endothelial cells, epithelial cells, and airway
smooth muscle cells (KleinJan, 2016). PDE3 deficiency or
pharmacological inhibition of PDE3 activity was shown to
reduce allergic airway inflammation and to improve airway
mucosal barrier function in allergic airway models (KleinJan,
2016). However, the role of PDE3 and the effects of PDE3i on
MC and basophil degranulation remained unknown.
This paper investigates the pathophysiological role of PDE3
in MCs and basophils via in vitro studies. Based on the
observations that i) PDE3 deficiency or PDE3i reduces allergic
airway inflammation (Beute et al., 2018) and that ii) epithelial
MCs are induced in a chronic house dust mite (HDM)-driven
asthma model (Beute et al., 2018; Li et al., 2019), III) and that
elevated cAMP levels have an inhibitory effect on exocytosis
(Alm, 1984) we hypothesize that PDE3 activity is important for
mast cell function. To determine how PDE3 deficiency or PDE3i
affects mast cell function, we analyzed mast cells in a chronic
HDM asthma model and investigated in vitro degranulation. We
observed that in cell cultures PDE3 inhibitors prevented and/or
attenuated stimulation-induced degranulation of bone marrow-
derived mouse mast cells, human peripheral blood mononuclear
cell (PBMC) basophils, LAD2 mast cell lines, and peripheral
blood-derived human mast cells.RESULTS
The Presence of Epithelial Mast Cells Is a
Sign of Chronic Allergic Airway
Inflammation
Evaluation of PDE mRNA transcripts indicated the
expression of PDE3B, PDE4A, PDE4B, and PDE4D in
mouse bone marrow-derived MCs. Hardly any PDE3A
expression was detected and no PDE4C (Supplementary
Figure 1). In earlier studies the presence of airway
epithelial MCs was demonstrated in allergic rhinitis andMay 2020 | Volume 11 | Article 470
Beute et al. PDE3 in Mast Cell Degranulationallergic asthma patients (KleinJan et al., 2000; Braunstahl
et al., 2003) as well as in chronic HDM-driven asthma models
(Li et al., 2019). MCs contribute to the development of
multiple features of asthma pathophysiology, both in an IgE-
dependent way and in an IgE-independent neurogenic-driven way
(Devos et al., 2016; Sibilano et al., 2016). By toluidine blue staining
we investigated the presence of MCs in airway epithelium samples
in a chronic HDM-driven asthma model. No epithelial MCs were
present in control phosphate buffered saline (PBS) mice, but they
did appear following HDM treatment. Degranulated—and
therefore activated—MCs were seen in HDM-exposed placebo-
treated wild-type (WT) mice (Figure 1A and insert). Mice lacking
PDE3 (Pde3−/−) or mice that received topical (Supplementary
Figure 2) PDE3i therapy showed lower (p < 0.01 and p < 0.005
resp.) epithelial MC numbers and those MCs present were in a
more granulated stage (Figure 1B). Other airway structures,Frontiers in Pharmacology | www.frontiersin.org 3including parenchyma and smooth muscle areas, were negative
for mast cells. In conclusion: epithelial mast cell numbers were
lower in a HDM-driven allergic airway inflammation mouse model
when PDE3 is lacking or when mice were treated with
PDE3 inhibitors.
PDE3 Plays a Pathophysiological Role in
Mast Cell Degranulation
In vitro-cultured mouse bone marrow-derived MCs (bmMCs)
were examined to investigate the role of PDE3 in MC
degranulation, using changes in CD107b and CD200r
expression as markers. Mast cell expression of surface CD200r
was shown to be increased after both IgE- and non-IgE-mediated
activation (Larson and Mitre, 2012). Overnight 2,4-
dinitrophenyl (DNP)-specific IgE-sensitized MCs and PBS
control MCs were stimulated with 10 ng/ml DNP-7-OVA forA
B
FIGURE 1 | Mast cell recruitment is impaired when PDE3 is targeted. (A) Representative photographs of toluidine blue (arrows pointed to mast cells) stained lung
section obtained from phosphate buffered saline (PBS) control mice and house dust mite (HDM) driven asthmatic mice. (B) Number of epithelial mast cells (MCs) per
mm length basal membrane. A Kruskal-Wallis test for multiple comparisons was used, followed by a Mann-Whitney U test. Error bars show mean values ± SEM (n=3
for PBS, n=6 for HDM groups; **P < 0.01; ***P < 0.005). Data are representative for three independent experiments.May 2020 | Volume 11 | Article 470
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only in DNP-specific IgE-loaded MCs and showed lower levels of
CD107b or higher levels of CD200r when compared to controls
(Figures 2A, C). Pde3−/− MCs were less activated upon FceR
cross-linking when measured with MCs degranulation markers
CD107b and CD200r (Figures 2A–D). Unstimulated WT and
PDE3−/− MCs showed no significant differences in median
fluorescence intensity (MFI) for CD107 or CD200r. InFrontiers in Pharmacology | www.frontiersin.org 4conclusion: mouse MCs lacking PDE3 were less activated upon
FceR cross-linking.
Clinically Available PDE3 Inhibitors Inhibit
Basophil Degranulation
To study the effect of PDE3i on the degranulation of human
basophils in the PBMCs fraction, a modified basophil-
degranulation test was performed. Basophils were defined asA
B
C
D
FIGURE 2 | Mast cell activation is impaired when PDE3 is targeted. (A, B) Bone marrow-derived mast cells (MCs) obtained form Pde3−/− mice and wild-type (WT)
control mice were sensitized with DNP-specific immunoglobulin E (IgE) or phosphate buffered saline (PBS), followed by stimulation with DNP-7 OVA. The mast cell
activation markers CD107b and CD200r were evaluated and data are shown as histogram overlays. (C) Dot plots with median fluorescence intensity (MFI) values
indicating reduction in CD107b and induction of CD200r upon DNP-7 OVA stimulation for WT and Pde3−/− mast cells. (D) DMFI for the indicated markers in MCs
from WT and Pde3−/− mice (KO). A Wilcox signed test and a Mann-Whitney U test was used for statistical evaluation. *P < 0.05. Plots represent (n=5) of one of two
independent experiments. MFI, median fluorescence intensity.May 2020 | Volume 11 | Article 470
Beute et al. PDE3 in Mast Cell DegranulationFcϵRI+HLA-DR−CD123+ cells, and further analyzed for CD63
and CD203c+ expression as degranulation markers. Because
CD63 expression is a marker for MC activation (Cop et al.,
2018; Taracanova et al., 2018), we determined that, whenFrontiers in Pharmacology | www.frontiersin.org 5basophils were activated by FceR cross-linking, the population
of CD63+CD203c+ cells increased from ~7 to ~31% (Figure
3A). As quantified by the proportions of CD63+CD203c+ cells,
ant i - IgE-act ivated basophi l s showed a diminishedA
B C D
E
FIGURE 3 | PDE3 inhibitors reduce FceR-mediated basophil activation. (A) Flow cytometry (FACS) plot of CD63/CD203 profiles of the CD123+FceR+ basophil cell
fractions from PBMCs that were treated with enoximone or diluent and stimulated with phosphate buffered saline (PBS) or anti-immunoglobulin E (IgE), as indicated.
(B–D) Dose-response to enoximone for proportions of CD63+CD203+ activated cells within the fraction of CD123+FceR+ PBMC (B), MFI values for CD63 (C), and
MFI values for CD203c (D). Values are mean ± S.E.M; n=3. (E) Capacity of the PDE3i enoximone, milrinone and cilostazol to inhibit activation of basophils, shown as
the proportions of CD63+CD203+ activated cells within the fraction of CD123+FceR+ PBMC. A Wilcox signed test and a Mann-Whitney U test was used. *P < 0.05;
**P < 0.01. Data are shown of one representative experiment from three independent experiments. MFI, median fluorescence intensity.May 2020 | Volume 11 | Article 470
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dose-dependent manner (Figures 3B–D). Attenuation of
these degranulation markers was achieved even at a low
dose of 4 µM enoximone. Other PDE3i (milrinone 100 µM
and cilostazol 100 µM) were able to impair basophil
degranulation as well (Figure 3E).
Mast Cell Line Degranulation Is Impaired
When PDE3 Is Targeted
HMC1 and LAD2 mast cell lines express PDE3 and PDE4
transcripts (Figure 4A). Attenuation of surface degranulation
markers in LAD2 cells was observed only if we treated the cells
with higher doses of enoximone (Supplementary Figure 3A).
For these experiments, sera obtained from HDM mono-allergic
(68-121 KU/l) or grass pollen (GP) mono-allergic (123-211 KU/
l) donors were used. Overnight passively sensitized LAD2 cells
with sera (controls: 20% serum or PBS) were stimulated with PBS
or HDM. When the cells were pretreated with enoximone in a
dose-dependent manner, followed by HDM stimulation (1 ng/
ml), the CD63- and CD203c-expression levels on the surface of
LAD2 (Figure 4B) cells were lower. Control LAD2 cells
sensitized with serum IgE obtained from isolated GP-allergic
subjects showed no degranulation upon HDM stimulationFrontiers in Pharmacology | www.frontiersin.org 6(Figure 4C). The marker CD203c presented less sensitive than
CD63 in MCs (Figure 4C).
PDE3 and Cyclic Adenosine
Monophosphate Both Contribute to the
Regulation of Mast Cell Degranulation
PDE3 inhibitors increase the intracellular cAMP and/or cGMP
concentrations. The effects of cAMP- or cGMP-analogue
treatment on the expression of CD63 on LAD2 cells were
evaluated (Supplementary Figures 3A–D) following 1 mM SP
stimulation. LAD2 cells showed reduced CD63 expression when
pretreated with enoximone (1,000 µM) followed by SP
stimulation. SP stimulation of LAD2 cells pretreated with a
high concentration of cAMP (1 mM) analogue was able to
prevent CD63 expression altogether (Supplementary Figure
3B). Treatment using cGMP (1 mM) analogue and stimulation
with SP showed no effect on CD63 expression (Supplementary
Figure 3C). One of the downstream targets of the cAMP
pathway is protein kinase A (PKA). To investigate the
molecular mechanism of PDE3 inhibition in LAD2 cells, we
stimulated LAD2 cells that were pretreated with PKA inhibitor
(Rp)-8-Br-cAMP (100 µM) with SP, and observed a significant
reduction of CD63 expression. This suggests that the LAD2-cellA
B C
FIGURE 4 | Effect of enoximone on FceR-mediated activation of human mast cell lines (A) Expression of PDE3 and PDE4 isoforms in the human mast cell lines
indicated, as determined by real-time (RT)-PCR. (B, C) Activation of HDM-stimulated serum immunoglobulin E (IgE) passively sensitized LAD2 cells, as determined by
flow cytometry. Data are shown as histograms overlays for CD63 (B) and median fluorescence intensity (MFI) (CD63 and CD203c) of flow cytometry (FACS)
measurements of enoximone (µM) pretreated and HDM (10 ng/ml) stimulated passive sensitized (HDM specific serum IgE) LAD2 cells (C). A Wilcox signed test was
used; *P < 0.05. Data are shown from one out of two independent experiments. MFI, median fluorescence intensity; HDM, house dust mite.May 2020 | Volume 11 | Article 470
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the cAMP-PKA pathway.
Next, the Ca2+ flux in MCs lacking PDE3 or treated with
PDE3i was investigated. Antigenic stimulation and neurogenic
stimulation were bypassed through the use of ionomycin, aFrontiers in Pharmacology | www.frontiersin.org 7calcium ionophore that opens all Ca2+ channels in a non-
specific way. Ionomycin induces Ca2+ flux in BmMCs; it
turned out that PDE3-deficient BmMCs showed a lower Ca2+
flux than control WT cells (Supplementary Figure 3E).
Likewise, when WT BmMCs were pretreated with enoximoneA
B
C
D
FIGURE 5 | FceR-mediated activation of human mast cell (HuMC) is impaired when PDE3 is targeted. (A) Flow cytometry analysis of cultured HuMC, gated on the
basis of forward and side scatter characteristics. Histograms overlays show flow cytometry (FACS) plot and dot plots graphs illustrating the expression of CD117 and
CD63, as indicated. (B) CD63 expression of enoximone (20 mM) pretreated passive sensitized HuMCs PBs control, HDM activated or ionomycin activated.
Quantification of HDM-specific serum immunoglobulin E (IgE) [(C) left] or non-HDM specific IgE [(C) right]. CD63 expression of HuMCs treated with enoximone 20
µM and subsequently PBS stimulated [(D) left panel]. CD63 expression of HuMCs treated with enoximone 20 µM and subsequently HDM stimulated [(D) middle
panel] or ionomycine stimulated [(D) right panel]. A Wilcox signed test was used; *P < 0.05. Data are shown from one out of two independent experiments. MFI,
median fluorescence intensity; HDM, house dust mite.May 2020 | Volume 11 | Article 470
Beute et al. PDE3 in Mast Cell Degranulation(20 µM), lower Ca2+ flux levels were reached (Supplementary
Figure 3F). These data suggest that mast cell degranulation is, at
least partly, regulated in a cAMP-Ca2+ dependent manner.
PDE3 Inhibition Inhibits Primary Human
Mast Cell Degranulation
To translate our findings to a more physiologically relevant
model, we investigated the effects of PDE3 inhibition in
primary human MCs. Peripheral blood-derived primary
human MCs (HuMCs) were subjected to flow cytometric
analysis (Figure 5A), notwithstanding the relatively high
autofluorescence (Figure 5A left panel), CD117 (Figure 5A
middle panel), and CD63 (Figure 5A right panel). Overnight
passive sensitized (20% serum) HuMCs, with sera obtained from
HDM mono-allergic or grass pollen (GP) mono-allergic donors
were subjected to flow cytometric analysis (Figure 5B) after
having treated with enoximone or diluent and stimulated with
PBS (Figure 5B left panel), HDM (Figure 5B middle panel), or
Ionomycine (Figure 5B right panel). The CD63 expression levels
of HuMCs changed when the cells were passively sensitized with
serum obtained from HDM-allergic donors (Figure 5C left
panel) but not GP mono-allergic donors (Figure 5C right
panel), followed by HDM stimulation (60 ng/ml), illustrating
that only specific IgE cross-linking induces MC degranulation.
Quantification indicated that HuMCs can, after passive
sensitization, be used to measure specific FceR cross-linking-
dependent MC degranulation and ionomycine-dependent MC
degranulation. CD63 expression was reduced when HuMCs were
treated with enoximone 20 µM and subsequently PBS stimulated
(Figure 5D left panel). MC degranulation induced by HDM (Figure
5D middle panel) or by ionomycine (Figure 5D right panel) was
reduced by pretreatment with enoximone 20 µM. Recapitulating:
both IgE-dependent and ionomycin (Ca2+)-dependent HuMC
degranulation can be reduced by PDE3 inhibition.DISCUSSION
This paper describe that MCs lacking PDE3, as well as LAD2
cells, HuMCs, and human basophils being treated with PDE3i,
showed restrained degranulation. High intracellular levels of
cAMP are associated with inhibition of MCs and basophil
degranulation (Alm, 1984). Transgenic mouse MCs lacking
PDE3 demonstrated that MCs without PDE3 react the same as
those treated with PDE3i. We used clinically relevant PDE3i to
investigate human basophils and human MCs illustrating the
role of PDE3 in the degranulation of these cells in allergic
airway inflammation.
MC degranulation is a process involving PDE3 and cAMP-
PKA. Having investigated three different types of cells in
addition to mouse MCs that lack PDE3 activity, all tests
confirm the pathophysiological role of PDE3 in MCs/basophils.
Our data show that inhibitors of cAMP-degrading enzymes
(PDE3) or increased intracellular levels of dibutyryl cAMP
(db-cAMP) prevent MC degranulation; this is consistent with
the observation by Serra-Pages et al., showing that, whenFrontiers in Pharmacology | www.frontiersin.org 8prostaglandin E2 (EP2)-dependent activation induces cAMP,
cAMP/PKA suppresses IgE-/antigen-dependent signals and
calcium influx, which is essential for MC degranulation (Serra-
Pages et al., 2012). Shichijo et al. observed that cAMP-elevating
agents, including PDE3i, inhibit cytokine production of MCs.
Unfortunately, the concentrations used (up to 10 µM) were
relatively low and were unable to reduce chemical mast cell
mediators (Shichijo et al., 1999). PDE inhibition elevated cAMP
and prevented MC activation (Shichijo et al., 1999). Measuring
CD63 expression or the production of IL1b are accepted
methods to determine SP-induced MC activation (Cop et al.,
2018; Taracanova et al., 2018). Mast cell activation was measured
in relation to CD63 expression. Cell surface CD63 is a marker
associated with membranes of intracellular vesicles which is
frequently used in basophil activation tests. In the current
study cells were treated for 30–60 min with PDEi and
subsequently stimulated as well for 30–60 min, which is longer
than in previous studies that failed to see any PDE3-inhibitor
effect. In addition, dose optimization appeared essential for every
specific PDEi in order to find the best effective inhibitory dose in
the bioassay. In general 10 µM is taken as a standard
concentration for PDEi; however, this study illustrates that 10 µM
is not always sufficient. We noticed that high concentrations
(1 mM) of enoximone did not affect the cell viability. Sole
enoximone treatment without stimulation had no effect on the
expression of CD63 and CD203c in LAD2 cells. The initial effect
of PDE3 inhibition is smooth muscle relaxation in humans. This
effect is already noticeable within 30 s after IV treatment (Beute,
2014; Sobhy et al., 2019). In smooth muscle cells, increased
cAMP inhibits myosin light chain kinase (MLCK), preventing
Ca2+ binding, thereby reducing MLC phosphorylation, and
hence relaxing the vascular smooth muscle (Prakash, 2016).
This mechanism is not unique for smooth muscle cells
(Prakash, 2016) or endothelial cells (Rigor et al., 2013) and
could also offer an explanation on how, in a cAMP-dependent
manner, MCs can be prevented to degranulate, with a role for
calmodulin. PDE3 seems to be involved in truncation of FcϵRIb
and mediates Ca2+-dependent microtubule formation (Cruse
et al., 2013), which prevents degranulation and cytokine release.
The data in this paper indicate that the release of Ca2+ via low
concentrations of ionomycin can be in part abrogated by PDE3
inhibition. This suggests that cAMP directly prevents binding of
Ca2+, which in turn prevents microtubule formation and
MC degranulation.
The reorganization of the actin cytoskeleton is under the
spatial control of Ca2+ cAMP–PKA signaling in smooth muscle
cells (Hocking et al., 2013). PDE3 plays a pathophysiological role
in allergic airway inflammation in a translational model (Beute
et al., 2018). The present study shows that targeting PDE3 has an
inhibitory effect on exocytosis of MCs and can be seen as a valid
bonus treatment in allergic asthma-related disease. PDE3
inhibitors are known to induce, within a few seconds,
filamentous (F)-actin changes of the cytoskeleton in epithelial
and endothelial cells (Liu et al., 2012), leading to enhanced
barrier function. Calcium is important for MC degranulation
and crucial for the granule migration in the cells, which is inMay 2020 | Volume 11 | Article 470
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opens Ca2+ channels, probably via the microtubules and or actin
cytoskeleton, leading to MC degranulation and activation. That
this process can be inhibited in MCs by PDE3 inhibition is novel;
how exactly this inhibition occurs is yet unknown.
Microdomains containing PDE3, PDE4, and adenylate
cyclase (AC) balance each other out; using either PDE3- or
PDE4-inhibitors, the net outcome might be in favor of immune
attenuation. Others suggest that PDE activity is sufficient to
restrict cAMP diffusion to specifically defined subcellular
compartments in certain cell types (Terrin et al., 2006; Oliveira
et al., 2010). These microdomains are formed by cytoskeleton
and might constitute an efficient barrier to cAMP diffusion, and
promote compartmentalized cAMP and PKA signals by allowing
cAMP to accumulate locally to a level sufficient to activate PKA.
This would prevent activation of PKA in the other locations of
the cytosol (Rich et al., 2000). The actin cytoskeleton would act as
a diffusional barrier for cAMP, and PDEs would be in control of
local cAMP levels in thus created microdomains (Monterisi et al.,
2012). Increased intracellular cAMP levels might account for the
decreased reactivity of basophils to venom allergen (Bauer
et al., 2007).
An important technique to illuminate this black box might be
measuring phosphorylation of cell signaling molecules such as
Syk Lyn, PLCg, and PIP2, since PIP2 via activated PLCg leads to
IP3 and DAG. IP3 stimulates the IP3R on the ER, leading to the
release of Ca2+. IP3R are phosphorylated by cAMP-dependent
protein kinase (PKA) (Taylor, 2017).
The anti-inflammatory effects of PDE3 inhibitors have been
established in other studies, and are illustrated by reduced serum
TNFa levels during PDE3 inhibition, when compared to
dobutamine-treated septic patients (Kern et al., 2001) and
reduction of macrophages as well as CD11b expression on
eosinophils (Beute et al., 2018). In alveolar epithelial cells LPS-
induced biosynthesis of pro-inflammatory cytokines is regulated
by cAMP and tightly controlled by PDEs, and can be reduced by
PDE inhibitors (Haddad et al., 2002).
Allergen-driven degranulation of mast cells and basophils is
one of the first steps in the allergy cascade resulting in local
inflammation. In the context of allergic airway inflammation
therapy the first choice to relieve symptoms is targeting basophil
and/or MC activation, or blocking the effect of mast cell
mediators. PDE4 inhibitors like roflumilast have shown to be
beneficial in the context of allergic inflammation; however,
because of the serious side effects they are not available for
allergy related diseases (Gupta, 2012). PDE3 inhibitors are
accompanied with less side effects (Metra et al., 2009) and are
in use as therapeutics for intermittent claudication (Barnett et al.,
2004). Clinical observations indicate immediate bronchodilation
in asthma patients and animal models when treated with PDE3
inhibitors enoximone and milrinone (Howell et al., 1995;
Fujimura et al., 1997; Myou et al., 1999).
Enoximone and its metabolites have the advantage over other
PDE3/PDE4 inhibitors in that they have been clinically used for
over 20 years, peri-operatively and in the ICU, to prevent organ
failure, as well as in having minimal side effects. Using low dosesFrontiers in Pharmacology | www.frontiersin.org 9of a clinically available PDE3 inhibitor like enoximone makes it
possible to avoid the serious side effects that were often seen
when asthma patients were treated with the very potent PDE4
inhibitors (Gupta, 2012). Investigational use of the PDE3
inhibitor enoximone shows improvement as well as attenuated
cell-driven symptomatology in asthmatic and allergic patients
(Beute unpublished). Clinical trials are underway to confirm
these observation in asthma patients. PDE3 inhibition is not only
a smooth muscle relaxant being beneficial in obstructive lung
disease (Leeman et al., 1987), but also improve mucosal barrier
function (Kern et al., 2001) and is in use as a rescue medication in
severe asthma (Leeman et al., 1987; Kern et al., 2001; Beute, 2014;
Sobhy et al., 2019). In conclusion, the present work has
established that the small molecule PDE3 inhibitor enoximone
is important in preventing basophil and mast cell degranulation.
PDE3 is a clinically relevant therapeutic target in the context of
allergic inflammation.METHODS
Animals
Pde3a−/− and pde3b−/− C57bl/6 mice were previously described
(Masciarelli et al., 2004; Choi et al., 2006) and showed no
abnormalities regarding T-cell development (data not shown).
WT C57bl/6 mice were bought from Charles River. Animals
were kept under specific pathogen-free conditions, provided with
water and food ad libitum and were used at the age of 6–
12 weeks.
Cell Lines and Serum
We took LAD2 cells, kindly provided by Kirshenbaum and
Metcalfe (National Institute of Allergy and Infectious Diseases,
Bethesda, Maryland), and HMC1 cells, a gift from Dr. J.H.
Butterfield (Mayo Clinic, Rochester, MN, USA) as a surrogate
for MCs. The human MC line HMC1 was kindly provided by Dr.
J.H. Butterfield (Mayo Clinic, Rochester, MN, USA). LAD2 is a
stem-cell factor (SCF) dependent human MC line (kindly
provided by Kirshenbaum and Metcalfe, National Institute of
Allergy and Infectious Diseases, Bethesda, Maryland). Serum
obtained from mono-allergic patients containing specific IgE for
either house dust mite (62 - > 100 kU/l) or GrassPollen (68 kU/l)
or (Birch >100 kU/l) was used for passive sensitization.
Study Approval
Peripheral blood cells were isolated from buffy coats of blood
donors (Sanquin Bloedvoorziening, NVT nr. 0014.03,
Rotterdam, the Netherlands). Serum samples obtained from
HDM and GP mono-allergic patients were initially collected
during routine diagnostic analysis in the Laboratory Medical
Immunology (Department of Immunology) of the Erasmus MC,
Rotterdam, Netherlands, and remaining material was made
available for this study. The Erasmus MC Medical Ethics
Committee approved this availability without the need for
informed consent, based on the use of fully anonymized
remaining diagnostic material without the patient beingMay 2020 | Volume 11 | Article 470
Beute et al. PDE3 in Mast Cell Degranulationsubjected to additional risk or medical procedures. All animal
experiments were approved by the Erasmus MC's Animal
Ethics Committee.
House Dust Mite Allergic Airway
Inflammation Model
To induce chronic airway inflammation, mice were anaesthetized
with isoflurane and treated intratracheally (i.t.) with 25 mg house
dust mite (HDM; Greer Laboratories) allergen extract in 50 µl
phosphate buffered saline (PBS) on day 0 or using PBS only
(KleinJan et al., 2014; Vroman et al., 2017) three times per week,
for six consecutive weeks; see Supplementary Figure 2.
Therapeutic Intervention by Intratracheal
Topical Application of Enoximone
Optimal dose of 25 µg enoximone versus diluent (Beute et al.,
2018) was administered with 25 µg HDM solution and used for
intratracheal treatment, or diluent (10% ethanol + 40%
propylene glycol + 50% Milli-Q pH 12) was administered with
25 µg HDM solution. Controls were treated with enoximone 25
µg administered with PBS or diluent administered with PBS.
Mice underwent enoximone treatment during the last 2 weeks of
the challenge period; see Supplementary Figure 1.
Histochemical Detection of Mast Cells
Toluid ine b lue , an ani l ine dye , s ta ins mas t ce l l s
metachromatically. Snap frozen lung tissue cryosections (6 µm)
were histochemically stained with toluidine blue (0.5% in HCL
0.5 M) at pH 0.5 for at least 5 min and observed and quantified
immediately (KleinJan et al., 1996). Quantification was
performed by counting the number of toluidine blue positive
cells per mm length basement membrane in the epithelium of
bronchioles of the airways, using an Axioskop 20 microscope
(Zeiss, Jena Germany) with an eyepiece graticule at a
magnification of 200 x (Beute et al., 2018)
Mouse Bone Marrow-Derived Mast Cells
Bone marrow (BM) cells were isolated from tibias and femurs of
WT and KO mice. The bones were crushed, cells were filtered
(100 µm) and washed. Red blood cells were lysed with lysis
buffer. The cells were cultured in RPMI 1640 medium (Life
Technologies) supplemented with 10 µg/ml interleukin 3 (IL-3),
10% heat inactivated fetal calf serum, 50 µg/ml gentamycin,
5*10-5 M b-mercaptoethanol at 37°C in 5% CO2 for 4–6 weeks.
By week 4, 95–98% of the cells must be MCs (Cop et al., 2018).
To confirm, the morphology of the bone marrow-derived MCs
(BMMCs) was assessed by toluidine blue staining to observe
mast cell granules.
Overnight DNP-specific IgE-sensitized MCs and PBS control
MCs were stimulated with DNP-7 OVA 10 ng/ml for 30 min.
Stained with antibodies against CD107bAF647 (Serotec) and
CD200rPE (eBiosciences) for 1 h at 4°C and washed. 4′,6-
Diamidino-2-phenylindole (DAPI) was used as a live/dead
marker. At least 2 * 103 cells were used per condition.Frontiers in Pharmacology | www.frontiersin.org 10Analysis of Phosphodiesterase Expression
RNA was isolated from mouse bone marrow-derived MCs and
LAD2 cells using a Total RNA Purification Kit (Sigma Aldrich).
Purity of the extracted RNA was verified using a Nanodrop 2000
Spectrophotometer (Thermo Fisher Scientific). From the RNA,
complementary DNA (cDNA) was reverse transcribed using a
Revert Aid First Strand cDNA Synthesis Kit (Thermo Fisher
Scientific). Quantitative PCR (qPCR) primers (for detailed
description of primer sequences see (Liu et al., 2012) specific
for all PDE3 and -4 isoforms were designed using the universal
probe library (Roche Diagnostics), and checked for efficiency.
Using SYBR Select Master Mix (Applied Biosystems), the cDNA
was analyzed via qPCR, using a 7300 Real-Time PCR System
(Applied Biosystems). Resulting data were normalized to relative
expression of household genes [b-actin in human and
hypoxanthine-guanine phosphoribosyl transferase (HPRT) in
mouse]. Resulting data were further visualized using the
comparative Ct (2−DCt) method (Wong and Medrano, 2005).
Phosphodiesterases Inhibition of
Basophils, LAD2 Cells, and Human
Mast Cells
Basophils
PBMCs were isolated from buffy coats of healthy blood donors by
lysing the red blood cells with lysis buffer (NH4CL) and washed
with RPMI twice (Beute et al., 2018). Whole-blood cells were
incubated with various PDE3 inhibitors (enoximone (10 µM),
milrinone (100 µM), cilostazol (100 µM), diluent [10% ethanol +
40% propylene glycol + 50%Milli-Q and pH12) (Dil enox) or PBS
or dimethyl sulfoxide (DMSO) resp.] for 30 min at 37°C next
stimulated with anti-IgE 1 mg/ml and washed and stained with
anti-CD63PeCy7, (eBioscience), anti-CD203cPE (Coulter), anti-
CD123BV650 (BD), anti-HLA-DRBV711 (BD), anti-FcϵRIFitc
(eBioscience), anti-FcϵRIAPC (eBioscience), and anti-CD11cAF700
(BD). DAPI or Aqua Live/Dead was used as live/dead marker.
Basophils were gated as FcϵRI+CD123+CD11c−HLADR− cells. At
least 5*105 PBMCs were analyzed and a minimum of 1*103
basophils were per condition were evaluated.
LAD2 Cells
LAD2 cells were sensitized passively with 20% serum overnight
(serum was harvested from HDM sensitized donors (62 -> 100
kU/l), followed by washing steps to remove excess unbound
serum-specific IgE. Then, the cells were treated with PDE3
inhibitor enoximone (10 or 50 µM) or diluent (10% ethanol +
40% propylene glycol + 50%Milli-Q and pH12) (Dil enox) for 30
min at 37°C, followed by stimulation with HDM [60 ng/ml
(Greer Laboratories)] or 1 mM substance P (Sigma) for 1 h.
Finally, the cells were washed followed by flow cytometry (FACS)
staining with CD63 PeCy7 (eBioscience), CD203cPE (Coulter)
for 1 h at 4°C and washed. DAPI was used as a live/dead marker.
At least 2 * 103 cells were used per condition.May 2020 | Volume 11 | Article 470
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HuMCs were cultured as previous described (Gauvreau et al.,
2000; Gaudenzio et al., 2016; Folkerts et al., 2020a; Folkerts et al.,
2020b). In brief, CD34 progenitors were isolated according to the
manufacturer's instructions in StemSpan medium (Stem Cell
Technologies), supplemented with ciprofloxacin. Human CD34
progenitors were cultured in StemPro-34 medium,
supplemented with 2 mM L-glutamine, 100 IU/ml penicillin,
100 g/ml streptomycin, 100 ng/ml recombinant human SCF
(rhSCF), 100 ng/ml recombinant human interleukin (rhIL)-6,
and 30 ng/ml rhIL-3 (first week only). Half of the cell culture
medium was replaced weekly with media containing 100 ng/ml
rhSCF and 100 ng/ml rhIL-6. Cells were used for experiments
after 7 to 10 weeks in culture (Folkerts et al., 2020a; Folkerts et al.,
2020b). CHO cells conditioned medium as a source of SCF was
used from 3 months onwards. Overnight, passively sensitized
HuMCs with 20% serum obtained from house dust mite (62 - >
100 kU/l) or grass pollen [68 kU/l), or birch pollen (> 100 kU/l)]
sensitized mono-allergic donors were washed, three times,
incubated with PDE3i enoximone 20 µM (1:1,000 20 mM) or
diluent (10% ethanol + 40% propylene glycol + 50% Milli-Q and
pH12) (Dil enox 1:1,000) for 60 min at 37°C. Subsequently, they
were stimulated with HDM (60 ng/ml), ionomycine 0.5 µg/ml
(Sigma), or diluent for 1 h at 37°C, washed, and stained with
anti-CD63PeCy7 and anti-CD117 BV471. At least 10*103 cells were
evaluated per condition.
Statistics
Reported values are shown as mean ± SEM. Statistical analyses
were performed with SPSS (SPSS Inc., Chicago, IL) using
Kruskal–Wallis one-way ANOVA, followed by Mann-Whitney
U-test. A Mann-Whitney U-test was only performed when the
one-way ANOVA test pointed to significance. A Wilcoxon sign-
rank test was used for paired samples. Resulting p values <0.05
were considered significant. Tests that did not reach significance
(p > 0.05) are not indicated.DATA AVAILABILITY STATEMENT
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SUPPLEMENTARY FIGURE 1 | PDE3 and PDE4 are expressed in mice mast
cells. Expression of PDE3 and PDE4 isoforms in bone marrow-derived mice mast
cells.
SUPPLEMENTARY FIGURE 2 | Experimental design.Experimental chronic
HDM-driven asthma design, showing intratracheal exposure to 25 mg of HDM
or PBS that was performed three times per week, as indicated by arrows. From
5 weeks onwards HDM/saline was admixed with placebo (diluent) or 25 mg
of enoximone. Analyses were performed at day 41, one day after the
last challenge.
SUPPLEMENTARY FIGURE 3 | Dose-response of cAMP and cGMP analogs
on CD63 expression by SP-activated LAD2 cells. (A-D) CD63 expression of LAD2
cells pre-treated for 30 min with increasing doses of enoximone (A), a cAMP analog
(B), a cGMP analog (C) and the PKA inhibitor (Rp)-8-Br-cAMP (D), followed by
stimulation with 1 mM substance P (SP) for 30 min. Data are shown as mean values
± SEM. A Mann-Whitney U test was used; * P < 0.05. (E,F) Ca2+ flux experiment
with bmMCs obtained from Pde3-/- mice and WT (E) and from WT treated with
PDE3i enoximone (20µM) or diluent (F). Data are shown of one representative
experiment from three independent experiments.REFERENCES
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